Current Clinical and Medical Education

Received 30 Jun 2024 | Revised 29 Jul 2024 | Accepted 20 Aug 2024 | Published Online 6 Sep 2024

Published By: Vision Publisher

CCME 02 (9), 70-83

ISSN 2942-0792

Antibody Microarrays as an Experimental Platform for the Analysis of Signal Transduction Networks, Protein Profiling, Semiquantitative Approaches, Quantification of Protein Phosphorylation, Autoimmune and Neurodegenerative diseases

Sihaab Haider Radhi Muheisen[1], Asawr Wahaab Hussein Ali[2]

[1,2]University of Babylon, College of Science, Department of Biology, Iraq

Abstract:

Current approaches' low sensitivity and sample capacity are major obstacles to time-resolved quantitative signalling network characterisation. Protein abundance and phosphorylation may now be quantitatively and comprehensively determined using antibody microarrays, an exciting new experimental platform. This study provides a concise overview of the evolution of quantitative microarray applications that use antibody-based capture of target proteins. Future applications will also rely heavily on antibody microarrays that use fluorescence detection. Nonetheless, there are workarounds for both approaches, and developments towards a nanoarray design that reduces the array format to a more manageable size show promise. Even though this form of microarray readout is not yet available for common use, significant strides were also achieved in the area of label-free detection. Finally, a standard method for quantitative investigation of signal transduction networks is now available: quantitative antibody microarray applications. Methods for detecting signals, detection limits, data processing, producing antibody microarrays, and finding the right detection and capture antibody pairs are all covered in depth.

Keywords: Antibody Microarrays, Protein Profiling, Protein Phosphorylation, Autoimmune, Neurodegenerative diseases

Corresponding Author: Sihaab Haider Radhi Muheisen†, University of Babylon, College of Science, Department of Biology, Iraq

Introduction

Interacting protein networks mediate signal transduction. With the right tools, we can interpret the cellular network and learn how signals move along these pathways, as well as how intracellular signalling differs in healthy and sick tissues. Traditional antibody-based techniques for studying protein turnover and post-translational changes, such Western blotting and enzyme-linked immunosorbent assay (ELISA) [1], can only identify a single protein at a time. Protein microarrays can multiplex the detection of several target proteins, unlike standard antibody-based methods. Because of the ability to simultaneously observe many signal transduction modules, this experimental platform has become a useful instrument for studying the interplay between these modules. In a traditional ELISA [2], a multititer plate needs to be coated with a large amount of antibody. The measurement's precision and sensitivity could be compromised if the target protein is depleted from the sample due to the relatively high concentration of capture antibody. Immunoassay miniaturisation, first used for the quantification of tiny molecules like hormones, was launched in the mid-1980s to address these limitations. Miniaturised antibody microarrays not only reduce consumable costs but also improve sensitivity and accuracy. Minimising sample consumption and assay time is achieved by using protein microarrays, which have the capability to multiplex numerous proteins. Monitoring the dose-dependent phosphorylation of important signal transduction components on antibody microarrays was a relatively new way to show how precisely tuned signal transduction is. There is a one-step or two-step process that can be used to directly or indirectly visualise the collected proteins [3]. Labelling the sample with the appropriate dye prior to incubation on the array is necessary for direct detection. The antigenic characteristics of a protein may be affected by this labelling procedure's masking of epitopes, which can disrupt the final readout. An antibody can be indirectly detected if it recognises a secondary antibody or if it carries a detectable label. Sandwich detection using antibody pairs should include antibodies derived from at least two distinct animal species, such as rabbit and mouse.... The specificity of antibody-based identification is enhanced by a two-step indirect detection method, since it is quite unlikely that two antibodies will recognise identical targets.



Figure 1. To detect signals, most antibody microarray methods use fluorescent dyes. Proteins in the sample or the antibodies used for detection can have these dyes covalently attached to them. There are three methods for detecting these dyes: direct detection with a labelled probe (A), indirect detection with a labelled detection

antibody (B), and indirect detection with a labelled secondary antibody (C). Resulting from 700 nm near-infrared (NIR) signal detection, this is a picture of a multipad slide (D). Unspecific interactions with unrelated proteins are illustrated by the spot morphology (E) profiles of a single pad. Although various methods were investigated, fluorescent dyes have a long history of use in signal detection on protein microarrays. As a rule, systems biology methods work well with protein microarray data because of the high signal-to-noise ratios they show. Given the massive volumes of data generated by multiplexed measurements, it was necessary to simultaneously implement appropriate methodologies and software tools for automated spot detection, signal intensity determination, background correction, and final data processing.

Antibody Microarrays for Protein Profiling

An Introduction to Semiquantitative Methods

In order to analyse proteins on a multiplexed scale [4], several antibody microarray methods were investigated. Although many methods use slides as a solid platform for antibody immobilisation, there is a wide variety of microarray content and methods for antibody immobilisation and target protein detection. It was shown by Haab and colleagues in 2001 that various proteins may be detected very sensitively using the microarray format. A direct detection approach and a collection of 115 antibody/antigen combinations were used to compare the sensitivity of antibody and protein microarrays [5]. By comparing antibody microarrays with protein microarrays, a tenfold lower detection limit was observed. This allowed for a detection limit of 1 ng/ml for the majority of proteins down to a partial concentration of 10-6. For this reason, antibody microarrays seemed to be the best method for identifying proteins present in low quantities in unprocessed mixtures. As an additional tool for comparative protein profiling, miniature antibody microarrays were used to track how ionising radiation affected a cancer cell line. Here, 146 distinct characteristics were detected fluorescence on antibody microarrays using a dye-swap experiment. There was a considerable increase in the expression of various apoptotic markers following radiation, suggesting that this platform could be valuable for assessing the efficacy of treatment [6]. In 2003, Nielsen and colleagues also investigated the basic processes involved in making antibody microarrays. The sensitivity of direct and indirect detection was compared in tests using recombinant proteins and crude biological mixtures. We used several cell lines to study the phosphorylation of epidermal growth factor receptors, which serves as a biological model. A more sensitive direct detection method could be used to detect recombinant proteins. Nevertheless, the indirect detection proved to be far more sensitive when tracking the activation of endogenously expressed cell surface receptors, suggesting that the sandwich method could be better suited for analysing intricate biological data [7]. The discrepancy could be explained by the fact that the introduction of a covalent fluorescent tag, which is necessary for direct detection, may work differently in complicated lysates compared to those with pure recombinant proteins. The two cell surface receptors, EGFR and ERBB2, which are members of the family of receptors for epidermal growth factor [8], and their activation upon ligand binding were profiled using the indirect detection method. We used phosphotyrosine antibody labelling with fluorescent dyes to detect receptor phosphorylation, which is a readout for receptor activation. The rapid dynamics of EGFR signal transduction were mirrored in the analysis of time-course studies. To further calibrate the amount of sample put on the slide, the abundance of the transferrin receptor was measured [9]. The use of protein microarrays for drug discovery research was demonstrated by studying the effects of a small molecule inhibitor applied at varied concentrations on signal transduction through the EGFR. Tyrosine phosphorylation dysregulation has been linked to numerous cancer forms. The development of targeted medicines became a priority because to the rapid attention given to the fact that mutations often cause the overexpression of specific kinases. To examine the patterns of posttranslational modifications of proteins [10], Gembitsky and colleagues (2004) presented an antibody microarray technique. After optimising the methodology, tyrosine phosphorylation profiling in response to growth factor receptor mediated activation could be achieved for up to 35 distinct proteins. Preparation of the samples required 1000–100,000 cells, depending on the kind of tissue. The protein abundance levels were compared using a ratiometric readout. According to the results obtained from Gleevec's BCR-ABL kinase inhibition, antibody microarrays can be utilised to analyse signalling pathways and measure the efficacy of cancer treatments that target specific receptors [11]. To profile the patterns of posttranslational modification of proteins involved in intracellular regulation, Ivanov and colleagues used a comparable strategy. Certain proteins were marked with fluorescent dyes after being immunoprecipitated. Antibody microarrays that particularly recognise posttranslational modifications, such as

phosphotyrosine, ubiquitin, or acetyllysine, were used to investigate the precipitated proteins later on. Depending on the relative amounts of posttranslational modifications, different signal intensities were observed. Using surface plasmon resonance as an optical sensor to detect target protein binding in real time was a breakthrough towards label-free detection on antibody microarrays. Protein expression profiling was accomplished in this proof-of-principle approach by spot-typing 382 antibodies against proteins from the mouse KIAA clone collection onto gold affinity chips. In mouse tissues, differential patterns of protein expression were found. Using a vacuum-driven filtration apparatus, a simplified prototype of an antibody array was created by immobilising 32 distinct antibodies on PVDF membrane. These antibodies were chosen to detect binding partners of a scaffolding protein. By analysing the variation of selected oligosaccharide structures with glycan-specific lectins, antibody microarrays were also used to monitor particular changes in the glycan structure of proteins. For this work, glass slides coated with ultrathin nitrocellulose [12] were used to print capture antibodies. Glycan structural analysis necessitated chemical derivatization of preexisting oligosaccharides attached to capture antibodies. The tumor-related antigens MUC1 (mucin-1) and CEA (carcino embryonic antigen) showed an increase in the sialyl Lewis acid structure, which is associated with cancer, according to lectin profiling. Additionally, commercial antibody arrays were utilised for the comparative analysis of protein abundance. After microarray incubation, the signal intensities of biological samples that had been labelled with a mixture of Cy3 and Cy5 fluorescent dyes were compared. Antibody microarrays have shown promise for protein profiling and tracking patterns of posttranslational modifications, according to the results. Unfortunately, no method allowed for the exact quantity of target proteins since it relied solely on comparative profiling [13] .

Protein Phosphorylation Absolute Quantification using Antibody Microarrays

Proteins and posttranslational changes can only be precisely quantified with the use of well-characterized standards, antibodies, or antibody pairs [14], as well as appropriate software for analysing results from multiplexed calibration slopes. When it comes to calculating absolute figures for protein turnover, none of the published or commercial methods incorporate a calibration phase. This means that these arrays can only provide a relative reading. A recent development that utilised the sandwich format in conjunction with near-infrared (NIR) fluorescence signal detection allowed for the multiplexed absolute quantification of protein phosphorylation. The phosphorylation of extracellular-signal regulated kinase (Erk1/2) and signal transducers and activators of transcription (Stat3) was used to study signalling through cytokine receptors [15]. The initial proof-of-concept methods included a number of novel procedures into the experimental design. To begin, LC/MS was used to ascertain the phosphorylation rate of standard proteins, which was necessary for the exact measurement of a specific posttranslational modification. For a reliable quantitative readout, it is essential to use antibody pairings that are compatible with quantitative detection in a multiplexed environment [16]. This is why the "antibodypair plot" was created: to compare and contrast various antibody pairs based on their dynamic range and accuracy. You can use this figure to identify antibody pairings in a multiplexed scenario or to quantify the level of cross reactivity in combinations of different detecting antibodies. The compact design enables regular, time-resolved observations using a small number of very sensitive primary cells (a few thousand cells at most). Differentiation between significant events [17], like Stat3 activation via a cytokine receptor, and minor events, such Erk1/2 activation, is made possible by the sensitivity and accuracy of this quantitative antibody microarray method. Both the amount and duration of protein phosphorylation were shown to be concentration-dependent, as demonstrated by the dose-response rates. Overall, quantitative antibody microarrays showed great promise as a method to study signal transduction tuning and module-to-module signal transduction interactions [18] .

Custom Curve Creation for Multipad Slides

To quantify specific target proteins [19], one needs a standard curve constructed from measurements of appropriate calibrator proteins. A calibration series was the data used by the Quantpro software to describe the correlation between the standard and the related signal intensities. A specific antibody combination was identified by the slope of the regression curve ($S = \Delta\text{intensity}/\Delta\text{concentration}$), which was obtained by fitting a linear regression on the calibration series. We summarised the signal intensities from time-resolved data as a measurement series [20]. A linear regression analysis of the calibration series was used to determine the concentration of each protein in a given sample. To

determine how well these estimations hold up under various conditions, such as standard linear regression error, measurement linearity, and signal repeatability, one might do bootstrap analysis [21].



Figure 2. Array layout for quantitative measurement in the multiplexed microspot immunoassay format. The 12×12 design allows accommodation of up to 15 different capture antibodies. Pad 1–6 was employed for incubation with six different concentrations of calibrator proteins.

Producing Quantitative Antibody Microarrays via Printing

Modern microdispensing without contact spotting

advances in technology have made contact-free sample delivery a reality. This allows for very precise sample delivery [22], which is crucial for quantitative microarray applications where reliable and repeatable printing is required. At predetermined intervals of 0.4 and 0.6 mm from the microarray surface, the droplets are released by the microdispensing device. Most noncontact spotters use what's called the reverse piezoelectric effect. Here, mechanical deformation of a crystal is the outcome of an electric pulse [23]. The presence of a piezo crystal in a glass capillary with liquid inside can induce the liquid to condense into a droplet at the capillary's tip. Experimental factors, like sample viscosity, the orifice diameter, and capillary type determine the precise spot size. Just by playing around with the voltage and pulse duration, you can fine-tune the size of the decrease. This method is perfect for microdispensing because of the tiny drop size, usually between 100 and 600 pl [24], that is characteristic of Antibody Microarrays in the Analysis of Signal Transduction Networks 163. Nevertheless, tiny particles originating from cell debris or dust can readily obstruct the narrow opening of the capillaries, which typically measures 50 to 100 µm. Therefore [25], microdispensing systems based on the piezo effect necessitate extremely pure samples and a housing to shield them from ambient dust. There are two ways samples can be delivered by multichannel microdispensing systems. When operating in simultaneous mode, all channels are spotted simultaneously, resulting in the formation of separate subarrays at a distance determined by the capillary offset [26]. Therefore, every sample in a subarray is printed by a specific capillary. The sequential mode, in contrast, uses a single capillary to transport samples to specific locations within each subarray. The subsequent sample is printed by the second capillary, and the process repeats thereafter. Printing in simultaneous mode with all capillaries in parallel uses more material, but is faster than sequential mode for sample delivery. Under this mode, there must be a matching position on the source for every subarray sample [27]. plate, as it is not possible to repeatedly address the same well with a single needle. The sequential mode, on the other hand, permits several addresses to the same sample well, allowing for the spotting of numerous replicate spots per subarray using a single sample. Nevertheless, a significant amount of time is consumed by the instrument's positioning adjustments [28], which are used to repeatedly realign the needle positions. To summarise, the printing time for the identical array using a single-capillary instrument and a multichannel equipment in sequential mode is approximately equal. Capillary alignment is another critical maintenance concern with multichannel equipment. For example, to make sure the microarray spots match up with the gal file in the analysis software [29], proper alignment is essential. Misdispensing can cause droplets to become smeared, dislocated, or even coated with satellites, which makes data interpretation much more difficult, if not impossible, thereafter. Detected as numerous smaller spots near the real spot

location, satellites degrade the subarray quality [30]. To ensure that all microarrays print the same arrays, online pressure control inside the piezo element is essential. This means that microarray printers have to find the sweet spot for sample supply pressure and keep it constant all the way through printing. The BioChip Arrayer System maintains the ideal pressure in the fluidic system with the help of an electronically controlled pressure transducer (PerkinElmer, Boston, USA; las.perkinelmer.com) [31]. It is possible to detect blocked capillaries right away. Another piezo microdispensing system (Scienion AG, Berlin, Germany; www.scienion.com) uses gravity control to keep the pressure just right, and also records the whole sample delivery process online. According to GeSiM GmbH of Großerkmannsdorf, Germany (www.gesim.de), nano-plotting instruments use a fluidic system that is linked to a silicon glass capillary through a metal shaft. Some manufacturers provide a configurable number of capillaries, and piezo-spotters are available with up to 16 channels to suit that number. A large number of channels, however, makes printing more complicated and necessitates changes to the capillary alignment for precise sample delivery. In addition, Arrayjet of Dalkeith, Scotland, UK (www.arrayjet.co.uk) has developed microdispensing devices that are well-suited to the manufacture of protein microarrays by utilising conventional inkjet technology [32]. In contrast to the previous instrument, which had a restricted number of glass or silicon capillaries, this one has a multichannel print head.

Upkeep of Systems for Non-Contact Microdispensing

Proper sample preparation and reagent quality standards, in addition to routine system maintenance, are essential for microdispensing applications. The liquid must fill the liquid system to the top, and the samples must not contain any particles that could block the capillaries. To ensure that the capillaries do not become blocked with debris from the cleaning operation, they must be detached [33]. b In detail, for spotting runs, the glass ends of the capillaries are immersed in the cleaning solution in order to aspirate double the amount of solution as is sampled. After that, to enhance the cleaning solution's efficacy, an ultrasonic pulse is generated by turning on the piezo element of the capillaries [34]. In order to stop proteins from sticking to the very hydrophilic surface that this process leaves behind, the capillaries must be silanized. To achieve the greatest results with silanization, aspirate 100 µl of methanol and then 100 µl of air. The capillaries plunge into an appropriate silane coating solution for 10 seconds while the air is administered in 20 seconds. Eliminating silane from the capillaries is accomplished by dispensing air [35]. The capillaries are flushed with water to wash away excess silane after the silane coating has dried for 5 minutes. the fluidic system requires the use of extremely pure water for the same reason. To avoid biological contamination, such as algae, it is important to flush the fluidic system on a regular basis. Additionally, gas bubbles caused by evaporation can be removed by flushing. One way to increase sample delivery and decrease the danger of satellite development is to siliconize the glass capillaries. Nonetheless, alternative, often individualised approaches do exist, and it is possible to print antibody arrays using capillaries that are either not silane-coated or have a silane coating on both the inside and outside. To eliminate any material accumulated on the glass, silanization involves cleaning the capillaries under extreme circumstances. After multichannel microdispensing devices are siliconized, they must have their capillary alignment and droplet shape regulated [36].

Identifying Potential Contacts

Steel pins are essential for the delivery of samples in contact spotting. You may classify pins as either solid or so-called split. The sample fluid is kept by cap-illary forces in the channel of a split pin, which also functions as a reservoir. Split pins enable sample distribution to numerous slides before the next sample is taken up, in contrast to solid metal pins [37], which require a new sample after spotting of single drops. One great thing about contact spotting is that it works just fine with samples that are extremely viscous or have vastly varying viscosities. The droplet's volume is highly sensitive to the sample fluid's viscosity. Therefore, signal analysis becomes more complicated and spot-to-spot volume variance increases when printing samples with varied viscosities. A workaround for this issue could be to normalise the readout and then use an extra assay to quantify the volumes of the spotted samples on the slide. You can always choose the sequential mode when you print. The pin's kind and size determine the drop size, which can range from high picoliters to low nanoliters per spot [38]. For tasks that do not necessitate the extreme precision of noncontact spotting, the less technically difficult contact spotting method is usually the way to go. Another spotting approach is the pin and ring technique. To cover an area equal to the ring's diameter in liquid, it is necessary to dip the ring into the sample and then remove it from the sample quickly. The liquid film is pressed to a

solid surface to create a spot by means of a solid pin. One of the main benefits of pin and ring spotting is that it may be used for exploratory techniques with a wide range of sample viscosities and surface chemistries [39].

Contact Spotting Instrument Maintenance

Cleaning and controlling the integrity of the spotting pins is the biggest maintenance challenge in contact spotting. Automatically, an ultrasonic device is used to clean and dry the pins before they are used in the following spotting run. Nevertheless, split pins do require occasional hand inspection. A magnifying glass can reveal any remaining sample that has settled into the split pins' passage. Mechanical tension from the printing process often deforms the pin points, which is a common issue.

Formats for the Slides

Proteins can be precisely quantified for a small number of targets using multipad slides, or for medium-scale protein profiling using single-pad slides. Using the microarray format to print multiple copies of a large number of distinct antibodies is crucial to discovery-type research. Capture antibodies need to be spotted in a minimum of six replicate spots per subarray for accurate quantitative analysis, and a higher number of replicate spots is required for robust calculation of calibration slopes. To be used in a multiplexed multititer plate format, identical subarrays are often printed on multipad nitrocellulose slides. Multititer plates, which can hold 18 spots per well, are another option for printing antibody arrays. With relation to the number of distinct proteins in. A proteome would benefit from a nanodesign that downsizes the protein microarray format. So far, a number of approaches have been considered. One example is the recent review of methods that are similar to electron beam lithography, which was used to create new nanostructured supports. As shown in the proof-of-principle methods, vials with volumes ranging from 6 to 4000 al can be used to conduct antibody-based experiments. While nanostructuring does make it possible to enhance the density of antibody arrays, the biggest obstacle to scaling this method up to meet the size of the cellular proteome is still finding appropriate antibody probes.

Finishes for Ends

The immobilised antibodies should remain functional until they are used, thanks to the surface coatings used to make antibody microarrays. In general, there are several structures that can be used to create a coating on glass that is compatible with proteins. To enhance protein immobilisation, direct coating merely adds functionality to the surface of the glass. Coatings made of other materials, on the other hand, create three-dimensional structures on glass surfaces that are ideal for absorbing and retaining proteins in their functional forms. The ability to bind proteins is the primary differentiator between flat and three-dimensional coatings. If you want reliable findings every time, you need an antibody-binding capacity of the membrane that is uniform across its whole surface. The surface coating's inactivation to prevent nonspecific binding is another critical issue; there are several approaches for this blocking. Antibody microarrays were tested on a wide variety of surfaces using a wide variety of detection techniques and protocols. When antibodies were detected in levels in the low femtomole range, the lowest detection limit was achieved using polyacrylamide-coated slides. It is worth noting that certain surface coatings, such as activated polystyrene and poly-l-lysine, bind proteins very well but do not maintain their activity. As a result, the detection limit for antibody microarrays is significantly larger than that for protein microarrays. There are alternative surface coatings that could be beneficial for antibody microarray applications; for example, dendrimer-coated slides and nitrocellulose slides both showed detection limits that were similar to those of protein microarrays. The significant visible-range autofluorescence of nitrocellulose, however, limits signal detection using nitrocellulose coatings. Guilleaume and colleagues verified this discovery. using a correlation between the autofluorescence intensity and the nitrocellulose coating thickness. Slides covered with polyacrylamide, rather than nitrocellulose, are ideal for detecting visible-range fluorescence signals. Additionally, when utilising visible-range fluorescence detection, glass slides coated with aldehyde silane, poly-l-lysine, or aminolysine consistently yielded improved results. Instead of using polyacrylamide-coated glass slides for antibody microarrays in multiplex immunoassay format, the possibility of using agarose-coated slides was investigated. Preparing consistently high-quality agarose-coated slides is a breeze [40]. Cy3 was used for visible-range sandwich detection of the chemokine MCP-1 (macrophage/monocyte chemotactic protein 1). There was little variance within and among arrays, and the signals were consistent and repeatable. Wingren and colleagues set out to create the robust supports for antibody microarrays of the future. They compared nitrocellulose-coated glass

slides to one made of silicon-based macroporous solid support, and found that it increased sensitivity, spot morphology, dynamic range, and reproducibility.

Detecting Signals

By contrasting the characteristics of three distinct pairs of fluorescent dyes—Cy3/Cy5, Alexa-647/Alexa-555, and ULS-biotin/ULSflu—Wingren and colleagues also assessed several solid support and fluorescent label combinations. There was a difference in the ratio of the fluorescence signal intensities of the three fluorescent dye pairs. Because of this finding, comparing samples using a two-color method is not as ideal. To analyse complicated materials using antibody microarrays, Wingren and colleagues suggest using a one-color method instead. The strong support with ULS-biotin/NHS-biotin labelling on black polymer Maxisorb slides produced the maximum level of sensitivity. In fact, when it comes to antibody microarrays, fluorescent dyes are by far the most used method for signal detection. Chemically activated compounds containing a wide variety of fluorescent dyes are readily accessible for use in labelling operations. These dyes can also be attached to secondary antibodies and tiny molecules like biotin. To select the optimal surface coating and label combination, optimisation is essential [41]. A regular microarray scanner can detect the commonly used fluorescent dyes Cy3 and Cy5. Alternatively, there are NIR dyes that work in the 700-900 nm region, which is another potential detection range. Reduced background and increased sensitivity are results of the low autofluorescence of biological molecules and nitrocellulose in the near-infrared (NIR) region. Use of the highly sensitive planar waveguide technology also allows for the quantification of fluorescence signals.

Analysis of Signals

To summarise, the majority of the signals on antibody arrays were identified using visible or near-infrared (NIR) detectable fluorescent dyes. Scanners having a resolution good enough for microarrays made of spots 100-300 µm in size can pick up the signals [42]. Common software allows for the quantification of signal intensities of individual spots, and there is a direct correlation between the mean or median signal intensities and the expression of the target protein. There are a number of software tools available for analysing signal intensities, such as GenePix, Quantarray, or ScanAlyze. The GenePix programme refers to the text files containing the picture analysis findings as ".gpr" files. A "gal" file summarises the information on the assembly of individual antibodies within the capture antibody grid. Using this gal file, we can associate a specific capture antibody name with the spot localisation data (row, column). In practise, the image analysis programme superimposes a grid over the microarray picture [43], and for each spot, it assigns a circular feature that corresponds to its location. Prior to calculating individual spot intensities, it is necessary to align the circular features such that they correspond with spots that are not perfectly positioned. In addition, the signal analysis programme of. allows users to choose how big the circular features are, so they can cover the most prominent pixels in every single area. When trying to quantify weak signals or areas with irregular shape, the software's automated resizing feature is useless. Alternatively, the standard deviation and overall data quality can be enhanced by using a fixed circle size that is defined by the area of the array's large spots. Other groups also used the fixed circle approach. The median is a decent way to account for the uneven distribution of signal intensities, which is particularly useful when dealing with confounding variables like dust, scratches, or spot size change, which have a stronger effect on the mean. To determine the protein concentration, we use the median, which provides a strong evaluation of the majority of pixels in a spot [44]. It is possible to reduce the noise level by subtracting the local background from the median of the signals, however this approach could be problematic for extremely weak or strong signals. One example is how nearby background readings are impacted by extremely bright areas; as a result, signal strength is typically correlated with the local background. To make the readout more robust, you can also increase the number of repeat places [45].

Programmes for Analysing Data

Transforming Unstructured Data into Concentration of Proteins

We built a specialised software programme called Quantpro to analyse antibody microarray data that was obtained using time-resolved quantitative measurements on multipad slides. The R statistical computing environment (http://www.r-project.org) is the foundation of this software package. Among the software's features are the ability to quantify target proteins, view time-resolved results, and compare antibody pairings. You may find the Quantpro utility at http://www.dkfz.de/mga/Quantpro. It has a straightforward GUI that lets you access the main features. Quantpro

reads and analyses a number of text files to prepare data and experimental information for the software package. The tab-delimited files that summarise the experimental information and capture antibody arrangement are necessary to accompany the gpr files that are generated from the microarray image analysis. The so-called slide description file summarises information in a tabular manner related to sample assignment, standard concentration, dilution factor, or detecting antibody. The antibody combination file also includes annotations for capture and detection antibodies. Additionally, there is commercial software that may be used to analyse protein microarray data (www.vigenetech.com).

Assessment of Linked Antibodies

One way to estimate the repeatability of individual measurements is to use the signal intensities from a calibration series. This is why we came up with a bootstrap-like method to cut down on the amount of measurements needed to calculate a calibration series by a specific percentage. The information from these locations is used to determine the reduced calibration series' predictive power as if it were an artificial measurement. It is necessary to record the absolute departure from the theoretically expected concentration after determining the concentration of the false measurements. By rearranging the values in the calibration and measurement series, this process is carried out one hundred times [46]. An antibody pair's accuracy is defined as the average deviation that results. As an extra quality metric, we also employ the dynamic range, which is the magnitude of the fluorescence intensity readout (calculated as the slope of the fitted linear regression times the calibration range). This method was used in the Quantpro software suite to quantitatively test the efficacy of various capture and detection antibody combinations and to computationally evaluate their quality. This is the antibody-pair plot tool. provides a visual representation of various quality metrics, including accuracy and dynamic range.

Microarrays of Antibodies for Use in Expression Profiling

The use of antibody microarrays for proteomics has grown in prominence in the last several years. They allow for the highly parallel detection of hundreds of analytes from extremely small sample quantities of only a few microliters as a multiplexing approach. Combined with this is a sensitivity that is comparable to that of the gold standard for protein quantification, ELISA, in the picomolar to femtomolar range. Optimising the experimental design, sample handling, labelling, incubation, and data processing stages is crucial for obtaining such sensitivities reliably and repeatedly for sets of hundreds of analytes at once. Over 800 proteins in plasma, urine, and tissue samples can be analysed using our existing antibody microarray techniques for multiplexed expression profiling studies.



Figure 3. Schematic representation of an antibody microarray experiment.

Antibody microarrays: A Current Overview

In order to analyse numerous targets in a single sample in parallel, antibody microarrays are constructed using immobilised antibodies. Modern techniques for designing antibodies and affinity reagents have contributed to the development of this technology [47]. Nano bodies, fragment antigen-binding (Fab)-fragments, and single-chain variable fragments (scFvs) are a few examples of the antibody derivatives that have been utilised to construct arrays. Recent years have also seen significant advancements in bioinformatics, new materials, and phage and ribosome display. A chemically functionalized or otherwise altered surface is used to immobilise antibodies, in a nutshell. Incubating a sample with soluble proteins of interest on the array after blocking the surface reactive groups allows the antibodies to capture the targeted proteins from the sample. Either fluorescently labelling the sample or adding a secondary detection reagent immediately reports the binding events that ensue. The versatility of antibody microarrays makes them appealing for research into many different biological processes [48]; examples of these include studying post-translational modifications, detecting toxins, analysing signal pathways, and studying protein-protein interactions. Arrays have opened doors to new disease biomarkers and the generation of distinct proteome signatures in the clinical setting through the comparison of healthy and diseased states. The future holds immense promise for this data, which will pave the way for more precise diagnoses and the capacity to monitor the progress of diseases and the effectiveness of treatments. When contrasted with more conventional, one-analytic approaches to protein analysis, such as Western blotting and enzyme-linked immunosorbent assays (ELISA), antibody microarrays have shown several benefits. Microarrays have lately seen improvements in standardisation and user-friendliness, in addition to being highly sensitive, having a high throughput, and requiring tiny sample amounts. From sample preparation to data analysis, antibody microarray experiments require less than 24 hours, which is significantly faster than conventional proteomics methodologies, particularly mass spectrometry (MS.(

Immune system disorders

Because of its variable symptoms and the absence of reliable biomarkers to differentiate it from other autoimmune disorders, systemic lupus erythematosus (SLE) can be difficult to diagnose [49]. Sixty SLE patients with varied degrees of disease activity, twenty-five RA patients, twenty-eight samples from other autoimmune diseases, twenty-four healthy controls, and a dozen samples from other diseases were screened using a DotScanTM antibody microarray by Lin et al. The antibody microarray profiles may be able to differentiate between individuals with active SLE and healthy controls. By confirming serum anti-dsDNA, complements C3 and C4, and microarrays enhanced the capacity to distinguish between semi-active and active SLE, the discriminative ability of traditional SLE diagnostics was enhanced, providing valuable information for improved disease management. An in-house antibody microarray was built by Carlsson et al. using 135 human recombinant single-chain fragment variables (scFv) that targeted immunological proteins. Researchers looked at 15 healthy volunteers, as well as patients with SLE and systemic sclerosis (SSc). Differentiating SSc from SLE can be problematic because SSc is an autoimmune illness that affects connective tissue. A potential proteomic signature to distinguish SLE and its severity from SSc was generated by the array's identification of forty differentially expressed proteins. This protein signature outperformed traditional clinical parameters such as ANA, anti-DNA, SLEDAI-2 k, C1q, C3, C4, and CRP when it came to disease classification. This finding suggests that antibody microarrays could be used to develop new disease-signatures that improve disease management in the clinic.

Contagious Illnesses

Antibody arrays allow for proteome-wide investigation of the several methods by which infections engage the immune system. The chronic gastritis-causing bacteria Helicobacter pylori infects almost half of the global population. Using 144 CD antibodies to assess the distribution of CD markers across uninfected and Helicobacter pylori infected gastric adenocarcinoma cells, Sukri et al. used the DotScanTM antibody microarray to determine the immune system's tolerance towards tumour cells in gastric cancer. It is worth noting that gastric adenocarcinoma cell line AGS infected with cagA + H. pylori exhibited elevated levels of CD27 expression, a marker crucial for the upkeep of the T cell population. Similarly, gastric cancer patients infected with H. pylori also showed increased levels of CD markers. This research provides more evidence that the immune system can tolerate gastric cancer and that different strains of H.

pylori take advantage of different variances in the immune response. Additionally, antibody arrays can be helpful in monitoring a dynamic physiological environment, such as the progression of a disease or the efficacy of a treatment. There was hepatitis C virus (HCV) related histological damage in 94% of patients after liver transplantation, and several of those patients had severe disease recurrence. In order to determine the severity of recurring diseases, predictive biomarkers are urgently required. The severity of HCV recurrence after transplantation was predicted by investigating peripheral blood samples taken from patients in four groups: pre-transplant, early-transplant, mid-transplant, and late-transplant. A CD antibody microarray was used for this purpose. By collecting blood samples at regular intervals from patients both before and after liver transplantation, researchers were able to monitor the disease environment, complete with internal controls. Severe recurrence was associated with a substantial rise in five CD markers: CD27, CD182, CD260, CD41, and CD34. Antibody arrays may help evaluate the severity of recurrent HCV illness following liver transplantation, according to this result. An array of 127 antibodies targeting gastric adenocarcinoma-related immune-regulatory antigens was developed by Ellmark et al. using the n-CoDeR library. Tey shown that specific protein expression profiles, including IL-9, IL-11, and MCP-4, can be detected in plasma proteomes and could be used as biomarkers for both tumours and infections [50]. The future of H. pylori-induced cancer may be brightened by these results, which might lead to better detection tools. Researchers have used bead-based antibody arrays to look for distinct protein patterns in the plasma of kids with malaria and its consequences. Out of one thousand proteins that were analysed, showed differential expression between children with malaria and healthy controls in the community. The severity of malaria was associated with thirteen more proteins. Two proteins in the muscles, creatine kinase and carbonic anhydrase 3, showed the most significant changes, suggesting muscle damage and lesions in children with cerebral malaria. These results show that inflammation and an imbalanced glucose metabolism are involved in severe forms of the disease.

Degenerative brain disorders

We can learn more about the pathogenesis of neurodegenerative diseases by the analysis of protein expression. The field of proteomics has recently made strides that could allow us to use antibody microarrays to hunt for new biomarkers. Researchers are now able to investigate cerebrospinal fluid (CSF) in addition to blood, thanks to advances in protocol creation. The Nilsson lab has performed multiple investigations in neuroproteomics employing antibodies from the Human Protein Atlas in conjunction with the suspension bead array tests. They identified GAP43, a cytoplasmic protein involved in neuronal development and regeneration, in CSF samples from MS patients; this protein shows promise as a biomarker for neurological disorders. A more recent study by Remnestål et al. analysed protein levels in cerebrospinal fluid (CSF) samples taken from several sets of patients with neurodegenerative diseases and from patients who had died. Among 376 antibodies, GAP43 and NRGN were identified as synaptic proteins related with Alzheimer's disease patients as compared to controls. A large-scale screening was carried out using plasma samples, cerebrospinal fluid (CSF), and brain tissue from MS patients. The screening began with the use of 4,500 antibodies on bead arrays. Both cerebrospinal fluid and plasma analysis revealed a group of proteins linked to different MS subtypes. Neurones near MS lesions were stained by using some of the candidate antibodies produced against IRF8, IL7, and METTL14 for immunofluorescence examination of brain tissue. This suggests that antibodies chosen from array-based assays for examination of bodily fluids can also offer further proof at the afflicted tissue. Last but not least, 367 amyotrophic lateral sclerosis (ALS) patients and 101 controls had their plasma tested for 278 proteins using the bead arrays. In conclusion, the study suggests that RGS18, neuroflament medium polypeptide (NEFM), and solute carrier family 25 (SLC25A20) are important proteins to further validate in separate sample sets due to their involvement in disease pathophysiology processes.

CONCLUSION

Advancements in antibody microarrays have shown that this platform can be used to study signal transduction pathways. For proteome analysis, two main varieties of antibody arrays were used. A medium-density array of antibodies containing several hundred to several thousand distinct antibodies forms the basis of the first method. As part of a proteome profiling project's preliminary work, medium-density arrays—which may be purchased from commercial vendors—were used. Another kind of antibody microarray allows for the targeted examination of specific signalling pathways by using a small number of antibodies. This array type is useful for verifying results from large-scale research and for quantifying changes in protein abundance and phosphorylation over time. From a technical

standpoint, we have constructed rigors protocols that utilise standard equipment, and antibody microarray technology has developed into a platform that is widely used. In addition to validating functional high-throughput screens, these platforms are valuable as complements to other technologies like mass spectrometry. The availability of highly specific and extensively studied antibodies, however, will remain the field's lynchpin. There is still a big problem in analysing protein microarray data. Software tools for microarray analysis were initially created for use with DNA microarrays, but they were subsequently extended to analyse protein microarray data as well. Having said that, DNA microarrays and protein microarrays are fundamentally different. To start, DNA microarrays have a far higher density, and their reading is always dependent on comparing two samples with distinct labels per spot. This is why the analysis procedure was modified to meet the requirements of protein microarrays, particularly in cases when a quantitative readout is produced. Quantpro is a software suite that allows for multiplexed sandwich quantitative measurements, data processing, and experimental data visualisation. An extra tool for assessing the precision and dynamic range of individual antibody pairs and multiplexed antibody pairs is also included of Quantpro. There should be both quantitative and qualitative criteria to assess the performance of antibodies in a multiplexed context, and there should be guidelines for the validation of binding reagents in protein microarray experiments. Future applications will also rely heavily on antibody microarrays that use fluorescence detection. Nonetheless, there are workarounds for both approaches, and developments towards a nanoarray design that reduces the array format to a more manageable size show promise. Even though this form of microarray readout is not yet available for common use, significant strides were also achieved in the area of label-free detection. Finally, a standard method for quantitative investigation of signal transduction networks is now available: quantitative antibody microarray applications.

REFERENCES

1. Korf U, Derdak S, Tresch A, Henjes F, Schumacher S, Schmidt C, Hahn B, Lehmann W, Poustka A, Beissbarth T, Klingmueller U (2008) Proteomics (in press) 3. Nielsen UB, Geierstanger BH (2004) J Immunol Methods 290:107
2. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, EmmertBuck MR, Roth MJ, Petricoin EF, Liotta LA (2001) Oncogene 20:1981
3. Sreekumar A, Nyati MK, Varambally S, Barrette TR, Ghosh D, Lawrence TS, Chinnaiyan AM (2001) Cancer Res 61:7585
4. Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK (2003) Proc Natl Acad Sci USA 100:9330 8. Gembitsky DS, Lawlor K, Jacovina A, Yaneva M, Tempst P (2004) Mol Cell Proteomics 3:1102
5. Ivanov SS, Chung AS, Yuan ZL, Guan YJ, Sachs KV, Reichner JS, Chin YE (2004) Mol Cell Proteomics 3:788
6. Usui-Aoki K, Shimada K, Nagano M, Kawai M, Koga H (2005) Proteomics 5:2396
7. Duffy HS, Iacobas I, Hotchkiss K, Hirst-Jensen BJ, Bosco A, Dandachi N, Dermietzel R, Sorgen PL, Spray DC (2007) J Biol Chem 282:9789
8. Chen SM, LaRoche T, Hamelinck D, Bergsma D, Brenner D, Simeone D, Brand RE, Haab BB (2007) Nat Methods 4:437
9. Bartling B, Hofmann HS, Boettger T, Hansen G, Burdach S, Silber RE, Simm A (2005) Lung Cancer 49:145
10. Celis JE, Moreira JMA, Cabezon T, Gromov P, Friis E, Rank F, Gromova I (2005) Mol Cell Proteomics 4:492
11. Smith L, Watson MB, O'Kane SL, Drew PJ, Lind MJ, Cawkwell L (2006) Mol Cancer Ther 5:2115
12. Wang J, Laschinger C, Zhao XH, Mak B, Seth A, McCulloch CA (2005) Biochem Biophys Res Commun 330:123
13. Lin HJ, Hsieh FC, Song H, Lin J (2005) Br J Cancer 93:1372
14. Löbke C, Laible M, Rappl C, Sahin Ö, Arlt D, Wiemann S, Poustka A, Sültmann H, Korf U (2008) Proteomics 8:1586–1594
15. Ghatnekar-Nilsson S, Dexlin L, Wingren C, Montelius L, Borrebaeck CAK (2007) Proteomics 7:540
16. Wingren C, Borrebaeck CAK (2007) Drug Discov Today 12:813
17. Angenendt P, Glokler J, Murphy D, Lehrach H, Cahill DJ (2002) Anal Biochem 309:253 22. Angenendt P, Glokler J, Sobek J, Lehrach H, Cahill DJ (2003) J Chromatogr A 1009:97

18. Guilleaume B, Buness A, Schmidt C, Klimek F, Moldenhauer G, Huber W, Arlt D, Korf U, Wiemann S, Poustka A (2005) Proteomics 5:4705
19. Seurynck-Servoss SL, White AM, Baird CL, Rodland KD, Zangar RC (2007) Anal Biochem 371:105
20. Lv LL, Liu BC, Zhang CX, Tang ZM, Zhang L, Lu ZH (2007) Electrophoresis 28:406 Antibody Microarrays in the Analysis of Signal Transduction Networks 175
21. Kim SJ, Park Y, Hong HJ. Antibody engineering for the development of therapeutic antibodies. Mol Cells. 2005;20(1):17–29.
22. Maynard J, Georgiou G. Antibody engineering. Annu Rev Biomed Eng. 2000;2:339–76.
23. Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–97.
24. Zahnd C, Amstutz P, Pluckthun A. Ribosome display: selecting and evolving proteins in vitro that specifcally bind to a target. Nat Methods. 2007;4(3):269–79.
25. Chandra H, Reddy PJ, Srivastava S. Protein microarrays and novel detec- tion platforms. Expert Rev Proteomics. 2011;8(1):61–79.
26. Yang L, Guo S, Li Y, Zhou S, Tao S. Protein microarrays for systems biology. Acta Biochim Biophys Sin (Shanghai). 2011;43(3):161–71.
27. Bergsma D, Chen S, Buchweitz J, Gerszten R, Haab BB. Antibodyarray interaction mapping, a new method to detect protein complexes applied to the discovery and study of serum amyloid P interactions with kininogen in human plasma. Mol Cell Proteomics. 2010;9(3):446–56.
28. He HJ, Zong Y, Bernier M, Wang L. Sensing the insulin signaling pathway with an antibody array. Proteomics Clin Appl. 2009;3(12):1440–50.
29. Ivanov SS, Chung AS, Yuan ZL, Guan YJ, Sachs KV, Reichner JS, Chin YE. Antibodies immobilized as arrays to profle protein posttranslational modifcations in mammalian cells. Mol Cell Proteomics. 2004;3(8):788–95.
30. Rucker VC, Havenstrite KL, Herr AE. Antibody microarrays for native toxin detection. Anal Biochem. 2005;339(2):262–70.
31. Sanchez-Carbayo M. Antibody microarrays as tools for biomarker discovery. Methods Mol Biol. 2011;785:159–82.
32. Sutandy FX, Qian J, Chen CS, Zhu H. Overview of protein microarrays. Curr Protoc Protein Sci. 2013;27:1.
33. Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, et al. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell. 2017;31(2):225–39.
34. Gujral TS, Karp RL, Finski A, Chan M, Schwartz PE, MacBeath G, Sorger P. Profling phospho-signaling networks in breast cancer using reversephase protein arrays. Oncogene. 2013;32(29):3470–6.
35. Berrade L, Garcia AE, Camarero JA. Protein microarrays: novel develop- ments and applications. Pharm Res. 2011;28(7):1480–99. 18. Mirus JE, Zhang Y, Li CI, Lokshin AE, Prentice RL, Hingorani SR, Lampe PD. Cross-species antibody microarray interrogation identifes a 3-pro- tein panel of plasma biomarkers for early diagnosis of pancreas cancer. Clin Cancer Res. 2015;21(7):1764–71.
36. Borrebaeck CA, Sturfelt G, Wingren C. Recombinant antibody micro- array for profling the serum proteome of SLE. Methods Mol Biol. 2014;1134:67–78.
37. Drobin K, Nilsson P, Schwenk JM. Highly multiplexed antibody sus- pension bead arrays for plasma protein profling. Methods Mol Biol. 2013;1023:137–45.
38. Schwenk JM, Gry M, Rimini R, Uhlen M, Nilsson P. Antibody sus- pension bead arrays within serum proteomics. J Proteome Res. 2008;7(8):3168–79.
39. Neiman M, Fredolini C, Johansson H, Lehtio J, Nygren PA, Uhlen M, Nils- son P, Schwenk JM. Selectivity analysis of single binder assays used in plasma protein profling. Proteomics. 2013;13(23–24):3406–10.
40. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960–76.
41. Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3 K pathway in human disease. Cell. 2017;170(4):605–35.
42. Brannmark C, Nyman E, Fagerholm S, Bergenholm L, Ekstrand EM, Ced- ersund G, Stralfors P. Insulin signaling in type 2 diabetes: experimental and modeling analyses reveal mechanisms of insulin resistance in human adipocytes. J Biol Chem. 2013;288(14):9867–80.

43. Boucher J, Kleinridders A, Kahn CR: Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol 2014, 6(1).
44. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med. 2009;15(3):89–100.
45. Yang Y, Lian S, Meng L, Qu L, Shou C. Antibody array revealed PRL-3 afects protein phosphorylation and cytokine secretion. PLoS ONE. 2017;12(1):e0169665.
46. Dexlin-Mellby L, Sandstrom A, Antberg L, Gunnarsson J, Hansson SR, Borrebaeck CA, Wingren C. Design of recombinant antibody microar- rays for membrane protein profling of cell lysates and tissue extracts. Proteomics. 2011;11(8):1550–4.
47. Mahlknecht P, Stemberger S, Sprenger F, Rainer J, Hametner E, Kirchmair R, Grabmer C, Scherfer C, Wenning GK, Seppi K, et al. An antibody microarray analysis of serum cytokines in neurodegenerative Parkinso- nian syndromes. Proteome Sci. 2012;10(1):71.
48. Zhang D, Qin Y. The paradox of elongation factor 4: Highly conserved, yet of no physiological signifcance? Biochem J. 2013;452(2):173–81.
49. Gao Y, Bai X, Zhang D, Han C, Yuan J, Liu W, Cao X, Chen Z, Shangguan F, Zhu Z, et al. Mammalian elongation factor 4 regulates mitochon- drial translation essential for spermatogenesis. Nat Struct. Mol Biol. 2016;23(5):441–9.
50. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401–10.
51. Lee Y, Kang DK, Chang SI, Han MH, Kang IC. High-throughput screening of novel peptide inhibitors of an integrin receptor from the hexa- peptide library by using a protein microarray chip. J Biomol Screen. 2004;9(8):687–94.
52. Bang JY, Kim EY, Kang DK, Chang SI, Han MH, Baek KH, Kang IC. Pharmacoproteomic analysis of a novel cell-permeable peptide inhibitor of tumor-induced angiogenesis. Mol Cell Proteomics. 2011;10